Important Rating: Credit Suisse Gives Diplomat Pharmacy (NYSE:DPLO) Lower Rating. What Is Next?

November 23, 2016 - By Darrin Black

Important Rating: Credit Suisse Gives Diplomat Pharmacy (NYSE:DPLO) Lower Rating. What Is Next?

Diplomat Pharmacy (NYSE:DPLO) Downgrade

Diplomat Pharmacy (NYSE:DPLO)‘s stock was cut to a Underperform by expert analysts at Credit Suisse. DPLO’s Neutral rating is no longer valid.

Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage

Out of 9 analysts covering Diplomat Pharmacy (NYSE:DPLO), 2 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 22% are positive. $55 is the highest target while $17 is the lowest. The $32.43 average target is 124.74% above today’s ($14.43) stock price. Diplomat Pharmacy has been the topic of 16 analyst reports since August 4, 2015 according to StockzIntelligence Inc. On Friday, June 24 the stock rating was initiated by Cowen & Co with “Market Perform”. The company was downgraded on Thursday, November 3 by Raymond James. The rating was initiated by UBS on Wednesday, October 21 with “Buy”. The firm has “Neutral” rating by Bank of America given on Wednesday, October 14. The stock has “Neutral” rating given by Mizuho on Wednesday, May 11. The company was downgraded on Thursday, November 3 by Leerink Swann. The firm has “Overweight” rating given on Wednesday, January 6 by Barclays Capital. The company was maintained on Tuesday, August 4 by Leerink Swann. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Friday, October 2. The company was downgraded on Thursday, November 3 by Avondale.

About 430,138 shares traded hands. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 52.17% since April 21, 2016 and is downtrending. It has underperformed by 57.50% the S&P500.

Insitutional Activity: The institutional sentiment increased to 1.82 in 2016 Q2. Its up 0.39, from 1.43 in 2016Q1. The ratio is positive, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.

Essex Investment Management Lc has 0.09% invested in the company for 15,642 shares. State Of Wisconsin Invest Board accumulated 0.04% or 267,900 shares. Principal Financial, a Iowa-based fund reported 261,464 shares. Suntrust Banks last reported 0% of its portfolio in the stock. Teachers Advsrs Incorporated, a New York-based fund reported 74,642 shares. Capstone Asset Mgmt has 10,910 shares for 0.01% of their US portfolio. Century Capital Mngmt Ltd Liability reported 70,542 shares or 0.27% of all its holdings. Creative Planning last reported 2,970 shares in the company. Wealthtrust holds 130 shares or 0% of its portfolio. The Pennsylvania-based Vanguard Group has invested 0.01% in Diplomat Pharmacy Inc (NYSE:DPLO). Great West Life Assurance Can, a Manitoba – Canada-based fund reported 3,400 shares. Rnc Capital Mngmt Ltd Liability Corporation has 0.26% invested in the company for 79,452 shares. Telemus Cap holds 0.03% or 6,425 shares in its portfolio. Independent Consultants accumulated 0.24% or 21,705 shares. Weatherbie Capital has invested 1.29% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO).

Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 2 selling transactions for $1.04 million net activity. Kaddis Atheer A had sold 20,000 shares worth $602,358.

Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The company has a market cap of $945.28 million. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. It has a 29.66 P/E ratio. The Firm operates through specialty pharmacy services segment.

According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”

DPLO Company Profile

Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).

More notable recent Diplomat Pharmacy Inc (NYSE:DPLO) news were published by: Fool.com which released: “Why Diplomat Pharmacy, Inc. Is Plunging Today” on November 03, 2016, also Prnewswire.com with their article: “Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Diplomat Pharmacy …” published on November 16, 2016, Fool.com published: “Why Diplomat Pharmacy, Inc. Shares Are Falling 13.6% Today” on October 26, 2016. More interesting news about Diplomat Pharmacy Inc (NYSE:DPLO) were released by: Businesswire.com and their article: “DPLO LOSS ALERT: Rosen Law Firm Reminds Diplomat Pharmacy, Inc. Investors of …” published on November 17, 2016 as well as Finance.Yahoo.com‘s news article titled: “Lawsuit for Investors in shares of Diplomat Pharmacy Inc (DPLO) announced by …” with publication date: November 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>